miR-4326 predicts adverse outcomes of triple-negative breast cancer and regulates cell growth and motility through modulating MED13
{{output}}
Background: Triple-negative breast cancer (TNBC) is one of the most malignant subtypes of breast cancer with a high recurrence rate and adverse prognosis. Due to the lack of reliable molecular targets, improving patients' outcom... ...
